

研究用試薬



Cytes Biotechnologies供給

専用培地、
操作手順書あり

ヒト初代肝細胞 (凍結バイアル)

Cytes Biotechnologies社（スペイン、バルセロナ）は、トランスレーショナル医療現場の発展と前進への貢献を目的とし、肝細胞単離やインビトロモデル用各種細胞製品の提供を行っております。同社の肝細胞製品は、スペイン及びヨーロッパの法規を遵守し、肝臓手術で切除された肝組織から単離、調製されています。HIV、HBV、HCV陰性であることを確認済みです。

<肝細胞製品一覧>

カタログ番号	製品名	包装	価格
HuCS	ヒト凍結肝実質細胞 (サスペンション培養用)	4-5 million cells/vial	60,000円
		6-12 million cells/vial	80,000円
HuCPM	ヒト凍結肝実質細胞 (単層培養用)	4-5 million cells/vial	99,000円
		6-12 million cells/vial	149,000円
HuCPI	ヒト凍結肝実質細胞 (酵素誘導試験用)	4-5 million cells/vial	138,000円
		6-12 million cells/vial	210,000円

※海外在庫を取り寄せる場合、別途海外輸送費100,000円/回を申し受け致します。

<専用培地一覧>

カタログ番号	製品	価格
MHT	Thawing media	15,000円/50mL
MHP	Plating media	28,000円/250mL
MHM	Maintenance media	42,000円/500mL

※海外在庫を取り寄せる場合、別途海外輸送費50,000円/回を申し受け致します。

海外在庫ロット情報は、
Cytes社ホームページに
て公開しております。

<https://www.cytesbiotechnologies.com/>

Cryopreserved Human Hepatocytes Available

Use the **filters** below to find the best lot for your needs.
Click on the "more info" column to get the **characterization datasheet**.
Use the **export option** on the right hand side of the filters to export the data
HuCPM: Certified **M**etabolism studies / **HuCPI**: Certified **I**nduction studies / **HuCPT**: Certified **T**ransporter studies



Plateable Non Plateable

Metabolism Certified: Induction Certified: Transporter Certified: Stock: 330 Cells/vial post thaw: 20 Viability post thawing: 100%

フィルターの追加

	Product Referer	More Info ↑	Lot ↑	Stock	Viability	Cells per vial (M)	Age	BMI	Gender	CYP1A n-fold	CYP2B n-fold	CYP3A n-fold
1	HuCPM+	I-M	https://goo.gl/zf BHum16061	28	87.1%	7.9	74	27.34	Male	21.79	2.39	2.66
2			https://goo.gl/8d6 BHU416043	112	92.7%	6.7	74	26.9	Female	26.88	6.9	11.76



株式会社 ケーエーシー

<付属データ>

- Donor Demographics
- Post Thaw information
- PHASE I: P450 activities expressed

+

【単層培養用、酵素誘導試験用】

- PHASE I: P450 activity & mRNA fold-induction
- PHASE II: UGTs & SULT activities expressed

平均細胞生存率

87%*

*Post Thaw information
2017年調査

Certification date: 1st February 2019

ANALYSIS CERTIFICATE

Lot#: BHum16016

DONOR DEMOGRAPHICS

Species	Sex	Race	Age	BMI	Smoker	Alcohol Use	Drug Use
Human	Male	Caucasian	70	26	No	No	No

Pathology	Medications	Serological Data
Colorectal cancer hepatic metastases	Paroxetine, duodart	Tested negative less than 3 months before surgery

Patient informed consent was obtained. The donor was serologically tested negative for following infectious diseases: HIV, Hepatitis B and C. Donor medical history were also examined prior to accepting this donor.

For in vitro use only, not to be used for clinical application. Products distributed by Cytes Biotechnologies may contain human material that should be treated as potentially hazardous.

CHARACTERIZATION FOR PLATEABLE CELLS

Lot#: BHum16016

Post Thaw Lot information

Number of viable cells/vial:

9.5 ± 1.3 × 10⁶ (n=2)

Post-thaw viability (%):

90.3 ± 2.7 (n=2)

Monolayer assessment*



Plateability: YES

Seeding density in 24 well recommended:

0.3 × 10⁶ cells/well in 0.5 ml

Cell morphology 24h

Cell morphology 96h



• PHASE I: CYP ACTIVITIES EXPRESSED IN pmol/min/mg protein (mean ± SD)

Enzyme	Induction (Specific Activity)			
	Basal Activity (pmol/min/mg protein) on day 1	Basal Activity (pmol/min/mg protein) on day 4	Induced Activity (pmol/min/mg protein) on day 4	n-Fold induction
CYP1A2	11.52 ± 1.69	1.95 ± 0.06	341.66 ± 84.99	175.08
CYP2B6	13.19 ± 0.31	8.09 ± 0.81	74.83 ± 5.34	9.25
CYP3A4	13.73 ± 0.54	0.94 ± 0.12	20.71 ± 5.20	21.93

Cryopreserved human hepatocytes were thawed and plated in 24well collagen I coated plates. Cells were overlaid (Corning) in Human Hepatocyte Maintenance Medium at first medium change at day of thawing. Treatment (n=2 per vehicle control [0.15% (v/v) DMSO] or inducers (Rifampicin, β-Naphthoflavone and Phenobarbital) began 1-day post-plating and continued for 72 hours. At the end of induction, monolayers were rinsed with PBS and incubated with probe substrate culture media. See Table 1 for information on each probe substrate. Metabolites were quantified by LC-MS and normalized to the vehicle control. The fold induction was calculated by dividing the induced activity by the vehicle basal activity on the same day.


• PHASE I: CYP450 mRNA induction

CYP (mRNA)	n-Fold Induction
CYP1A2	11
CYP2B6	22
CYP3A4	191

Cryopreserved human hepatocytes were thawed, plated in 24well collagen I coated plates in Hepatocyte Plating Medium overlaid with Matrigel® (Corning) in Human Hepatocyte Maintenance Medium at first medium change at day of thawing. Treatment (n=2 per compound) with vehicle control [0.15% (v/v) DMSO] or inducers (Rifampicin, β-Naphthoflavone and Phenobarbital) began 1-day post-plating and continued for 72 hours. At the end of the period, RNA was isolated for mRNA analysis.

サスペンション培養用ロットには、Viabilityの経時的変化（融解後0～5時間まで）のデータが付属します。

Time (h)	0	0.5	1	1.5	2	3	4	5
Viability (%)	86.0	77.8	78.6	78.9	74.0	64.4	43.2	37.8



お問い合わせは・・・



株式会社 ケーエーシー
KAC <http://www.kacnet.co.jp/>

▶ 試薬営業グループ

〒110-0005
東京都台東区上野1丁目4-4藤井ビル3階
TEL:03-5807-7162 FAX:03-5807-7163
e-mail:shiyaku-info@kacnet.co.jp